High hopes new drug could be a ‘game changer’ against long-incurable Alzheimer’s
September 1, 2016
The Star | August 31, 2016
One strength is that aducanumab targets a particularly nasty variety of amyloid known as “oligomers,” according to Dr. Sandra Black, a neurology professor with the University of Toronto and Sunnybrook Health Sciences Centre, which will serve as a clinic site for the antibody’s Phase 3 trials. Read more.